New drug combination shows promise against childhood brain cancer
(Sanford-Burnham Prebys Medical Discovery Institute) Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified a new combination therapy for the most aggressive form of medulloblastoma, a fast growing pediatric brain cancer. In a study published online today in Cancer Cell, they show that panobinostat, an HDAC inhibitor, combined with a PI3K inhibitor, significantly slows growth of MYC-driven medulloblastomas. These results are expected to lead to a clinical trial to confirm the benefits of the novel drug combination.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Childhood Cancer | Clinical Trials | Medulloblastoma | Neurology | Pediatrics | Study